MAPT and Alzheimer disease: CSF Aβ 1–42 levels combined with total Tau (tTau) and phosphorylated Tau (pTau) are currently used as diagnostic biomarkers for AD with a high sensitivity and specificity [19,20,21,22], ameliorating the diagnostic accuracy in the very early stages of the disease.